30 results on '"Koppie T"'
Search Results
2. The Effect of Sirolimus on Prostate-Specific Antigen (PSA) Levels in Male Renal Transplant Recipients Without Prostate Cancer
- Author
-
Chamie, K., Ghosh, P. M., Koppie, T. M., Romero, V., Troppmann, C., and deVere White, R. W.
- Published
- 2008
3. Bladder Cancer Outcome and Subtype Classification by Gene Expression
- Author
-
Blaveri, E., Simko, J. P., Korkola, J. E., Brewer, J. L., Baehner, F., Mehta, K., Devries, S., Koppie, T., Pejavar, S., Carroll, P., and Waldman, F. M.
- Published
- 2006
4. Renal cell carcinoma with inferior vena cava involvement: Prognostic effect of tumor thrombus consistency on cancer specific survival
- Author
-
Mager R., Daneshmand S., Evans C. P., Palou J., Martinez-Salamanca J. I., Master V. A., McKiernan J. M., Libertino J. A., Haferkamp A., Capitanio U., Carballido J. A., Chantada V., Chromecki T., Ciancio G., Gontero P., Gonzalez J., Hohenfellner M., Huang W. C., Koppie T. M., Espinos E. L., Lorentz A., Montorsi F., Novara G., O'Malley P., Pahernik S., Moreno J. L. P., Pruthi R. S., Faba O. R., Russo P., Scherr D. S., Shariat S. F., Spahn M., Terrone C., Tilki D., Vazquez-Martul D., Donoso C. V., Vergho D., Wallen E. M., Zigeuner R., Mager, R., Daneshmand, S., Evans, C. P., Palou, J., Martinez-Salamanca, J. I., Master, V. A., Mckiernan, J. M., Libertino, J. A., Haferkamp, A., Capitanio, U., Carballido, J. A., Chantada, V., Chromecki, T., Ciancio, G., Gontero, P., Gonzalez, J., Hohenfellner, M., Huang, W. C., Koppie, T. M., Espinos, E. L., Lorentz, A., Montorsi, F., Novara, G., O'Malley, P., Pahernik, S., Moreno, J. L. P., Pruthi, R. S., Faba, O. R., Russo, P., Scherr, D. S., Shariat, S. F., Spahn, M., Terrone, C., Tilki, D., Vazquez-Martul, D., Donoso, C. V., Vergho, D., Wallen, E. M., and Zigeuner, R.
- Subjects
Adult ,Aged, 80 and over ,Male ,Venous Thrombosis ,renal cell carcinoma ,thrombus consistency ,cancer specific survival ,Vena Cava, Inferior ,Middle Aged ,Prognosis ,Survival Analysis ,Kidney Neoplasms ,venous tumor thrombus ,Humans ,Female ,Neoplasm Invasiveness ,Carcinoma, Renal Cell ,Aged ,Follow-Up Studies ,Retrospective Studies - Abstract
Background: Renal cell carcinoma forming a venous tumor thrombus (VTT) in the inferior vena cava (IVC) has a poor prognosis. Recent investigations have been focused on prognostic markers of survival. Thrombus consistency (TC) has been proposed to be of significant value but yet there are conflicting data. The aim of this study is to test the effect of IVC VTT consistency on cancer specific survival (CSS) in a multi-institutional cohort. Methods: The records of 413 patients collected by the International Renal Cell Carcinoma–Venous Thrombus Consortium were retrospectively analyzed. All patients underwent radical nephrectomy and tumor thrombectomy. Kaplan–Meier estimate and Cox regression analyses investigated the impact of TC on CSS in addition to established clinicopathological predictors. Results: VTT was solid in 225 patients and friable in 188 patients. Median CSS was 50 months in solid and 45 months in friable VTT. TC showed no significant association with metastatic spread, pT stage, perinephric fat invasion, and higher Fuhrman grade. Survival analysis and Cox regression rejected TC as prognostic marker for CSS. Conclusions: In the largest cohort published so far, TC seems not to be independently associated with survival in RCC patients and should therefore not be included in risk stratification models. J. Surg. Oncol. 2016;114:764–768. © 2016 Wiley Periodicals, Inc.
- Published
- 2016
5. 1043 Impact of synchronous metastasis distribution on survival in renal cell carcinoma after radical nephrectomy with tumor thrombectomy
- Author
-
Tilki, D., primary, Hu, B., additional, Nguyen, H., additional, Dall'Era, M., additional, Thieu, W., additional, Bertini, R., additional, Carballido, J., additional, Chromecki, T., additional, Ciancio, G., additional, Daneshmand, S., additional, Gontero, P., additional, Gonzalez, J., additional, Haferkamp, A., additional, Hohenfellner, M., additional, Huang, W., additional, Koppie, T., additional, Lorentz, A., additional, Mandel, P., additional, Martinez-Salamanca, J., additional, Master, V., additional, Matloob, R., additional, McKiernan, J., additional, Mlynarczyk, C., additional, Montorsi, F., additional, Novara, G., additional, Pahernik, S., additional, Palou, J., additional, Pruthi, R., additional, Ramaswamy, K., additional, Rodriguez, Faba O., additional, Russo, P., additional, Shariat, S., additional, Spahn, M., additional, Terrone, C., additional, Vergho, D., additional, Wallen, E., additional, Xylinas, E., additional, Zigeuner, R., additional, Libertino, J., additional, and Evans, C., additional
- Published
- 2014
- Full Text
- View/download PDF
6. Neoadjuvant Chemotherapy Use in Bladder Cancer: A Survey of Current Practice and Opinions
- Author
-
Cowan, N. G., primary, Chen, Y., additional, Downs, T. M., additional, Bochner, B. H., additional, Apolo, A. B., additional, Porter, M. P., additional, La Rochelle, J. C., additional, Amling, C. L., additional, and Koppie, T. M., additional
- Published
- 2014
- Full Text
- View/download PDF
7. 263 IMPACT OF CARDIOPULMONARY BY-PASS IN CANCER-SPECIFIC SURVIVAL IN PATIENTS WITH RENAL CELL CARCINOMA AND LEVEL III/IV THROMBUS
- Author
-
Martinez-Salamanca, J.I., primary, Capitanio, U., additional, Huang, W.C., additional, Sorcini, A., additional, Bertini, R., additional, Bianco, F.J., additional, Carballido, J., additional, Ciancio, G., additional, Herranz, F., additional, Haferkamp, A., additional, Koppie, T., additional, Martinez-Ballesteros, C., additional, Briganti, A., additional, Palou, J., additional, Pontes, E., additional, Russo, P., additional, Terrone, C., additional, Volpe, A., additional, and Libertino, J.A., additional
- Published
- 2011
- Full Text
- View/download PDF
8. Histopathology in surgically treated renal cell carcinoma: Is there a survival difference when stratified by stage?
- Author
-
Keegan, K. A., primary, Hellenthal, N. J., additional, Chamie, K., additional, and Koppie, T. M., additional
- Published
- 2009
- Full Text
- View/download PDF
9. The effect of rapamycin on PSA kinetics in men without prostate cancer
- Author
-
Chamie, K., primary, Ghosh, P. M., additional, Koppie, T. M., additional, Romero, V., additional, Troppman, C., additional, and deVere White, R. W., additional
- Published
- 2008
- Full Text
- View/download PDF
10. Effect of socioeconomic status and race on outcome after radical prostatectomy for localized prostate cancer
- Author
-
Koppie, T. M., primary, Robbins, A. S., additional, Mills, P. K., additional, and deVere White, R. W., additional
- Published
- 2008
- Full Text
- View/download PDF
11. V38 EXTENDED LAPAROSCOPIC PELVIC LYMPH NODE DISSECTION (LND) FOR PROSTATE CANCER
- Author
-
Secin, F.P., primary, Koppie, T., additional, Touijer, K., additional, and Guillonneau, B., additional
- Published
- 2007
- Full Text
- View/download PDF
12. Bladder Cancer Stage and Outcome by Array-Based Comparative Genomic Hybridization
- Author
-
Blaveri, E., primary, Brewer, J.L., additional, Roydasgupta, R., additional, Fridlyand, J., additional, DeVries, S., additional, Koppie, T., additional, Pejavar, S., additional, Mehta, K., additional, Carroll, B., additional, Simko, J.P., additional, and Waldman, F.M., additional
- Published
- 2006
- Full Text
- View/download PDF
13. The impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients (pts) with transitional cell carcinoma (TCC) of the bladder
- Author
-
Dash, A., primary, Koppie, T., additional, Vora, K., additional, Bochner, B., additional, and Galsky, M. D., additional
- Published
- 2005
- Full Text
- View/download PDF
14. Novel method of assessing surgical margin status in laparoscopic specimens
- Author
-
Meng, M. V., Koppie, T. M., Duh, Q. Y., and Stoller, M. L.
- Published
- 2001
- Full Text
- View/download PDF
15. The impact of lymphovascular space invasion in pure pT1 tumors of the bladder: A clinical pathologic study of 73 cases
- Author
-
Olgac, S., Koppie, T., Tickoo, S. K., Hikmat Al-Ahmadie, Fine, S., Gopalan, A., Dalbagni, G., and Reuter, V. E.
16. Small cell carcinoma of the urinary bladder: A clinicopathologic study of 55 cases
- Author
-
Olgac, S., Koppie, T., Saunders, N., Bernard Bochner, and Reuter, V. E.
17. Urinary Comprehensive Genomic Profiling Correlates Urothelial Carcinoma Mutations with Clinical Risk and Efficacy of Intervention.
- Author
-
Bicocca VT, Phillips KG, Fischer DS, Caruso VM, Goudarzi M, Garcia-Ransom M, Lentz PS, MacBride AR, Jensen BW, Mazzarella BC, Koppie T, Korkola JE, Gray JW, and Levin TG
- Abstract
The clinical standard of care for urothelial carcinoma (UC) relies on invasive procedures with suboptimal performance. To enhance UC treatment, we developed a urinary comprehensive genomic profiling (uCGP) test, UroAmplitude, that measures mutations from tumor DNA present in urine. In this study, we performed a blinded, prospective validation of technical sensitivity and positive predictive value (PPV) using reference standards, and found at 1% allele frequency, mutation detection performs at 97.4% sensitivity and 80.4% PPV. We then prospectively compared the mutation profiles of urine-extracted DNA to those of matched tumor tissue to validate clinical performance. Here, we found tumor single-nucleotide variants were observed in the urine with a median concordance of 91.7% and uCGP revealed distinct patterns of genomic lesions enriched in low- and high-grade disease. Finally, we retrospectively explored longitudinal case studies to quantify residual disease following bladder-sparing treatments, and found uCGP detected residual disease in patients receiving bladder-sparing treatment and predicted recurrence and disease progression. These findings demonstrate the potential of the UroAmplitude platform to reliably identify and track mutations associated with UC at each stage of disease: diagnosis, treatment, and surveillance. Multiple case studies demonstrate utility for patient risk classification to guide both surgical and therapeutic interventions.
- Published
- 2022
- Full Text
- View/download PDF
18. Prophylactic antibiotics following radical cystectomy reduces urinary tract infections and readmission for sepsis from a urinary source.
- Author
-
Werntz RP, Martinez-Acevedo A, Amadi H, Kopp R, La Rochelle J, Koppie T, Amling C, and Sajadi KP
- Subjects
- Aged, Aged, 80 and over, Female, Follow-Up Studies, Humans, Male, Middle Aged, Prognosis, Quality Improvement, Sepsis etiology, Urinary Tract Infections etiology, Anti-Bacterial Agents therapeutic use, Antibiotic Prophylaxis methods, Cystectomy adverse effects, Postoperative Complications prevention & control, Sepsis prevention & control, Urinary Bladder Neoplasms surgery, Urinary Tract Infections prevention & control
- Abstract
Introduction: Urinary tract infections (UTI) and sepsis contribute significantly to the morbidity associated with cystectomy and urinary diversion in the first 30 days. We hypothesized that continuous antibiotic prophylaxis decreased UTIs in the first 30 days following radical cystectomy., Methods: Patients with urothelial carcinoma of the bladder who underwent a radical cystectomy with urinary diversion for bladder cancer at Oregon Health and Science University from January 2014 to May 2015 were included in the study. The ureteral stents were kept for 3 weeks in both groups. In October 2014, we enacted a Department Quality Initiative to reduce UTIs. Following the initiative, all radical cystectomy patients were discharged home on antibiotic prophylaxis following a postoperative urine culture obtained during hospitalization. To evaluate the effectiveness of the initiative, the last 42 patients before the initiative were compared to the first 42 patients after the initiative with regard to the rate of UTI in the first 30 days following surgery. We used a combination of comprehensive chart review and the American College of Surgeons' National Surgical Quality Improvement Program (NSQIP) to determine UTI and readmission for urosepsis in the first 30 days following surgery. This ensured accurate capture of all patients developing a UTI., Results: A total of 12% in the prophylactic antibiotic group had a documented UTI, whereas 36% in the no antibiotic group had a urinary tract infection (P<0.004). A total of 1 (2%) patient in the antibiotic group was readmitted for urosepsis whereas 7 (17%) patients in the no antibiotic group were admitted for urosepsis (P = 0.02). There was no association noted between urine culture at discharge and the development of UTI in the 30-day postdischarge period (P = 0.75). The median time to UTI was 19 days and the most common organism was Enterococcus (32%). Thirty-percent of patients not receiving prophylaxis developed a UTI 1 day after ureteral stent removal. No patients had a UTI following stent removal in the prophylaxis group. No adverse antibiotic related events were noted., Conclusion: Prophylactic antibiotics in the 30 days following radical cystectomy is associated with a significant decrease in urinary tract infections and readmission from urosepsis after surgery., (Copyright © 2018 Elsevier Inc. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
19. Highlights from the first symposium on upper tract urothelial carcinoma.
- Author
-
Matin SF, Shariat SF, Milowsky MI, Hansel DE, Kassouf W, Koppie T, Bajorin D, and Grollman AP
- Subjects
- Congresses as Topic, Humans, Carcinoma, Transitional Cell, Urologic Neoplasms
- Abstract
Objectives: Upper tract urothelial carcinoma (UTUC) is a rare disease in Western countries and garners little focused attention in urologic and oncologic circles. We report highlights from the first symposium on UTUC., Methods: All participants were asked to provide a summary of their presentation to be included as part of these proceedings. Submitted summaries were synthesized into this document. All contributors reviewed and provided input on the final draft., Results: Five highlights are included in this report, including landmark research that not only reveals the likely cause of Balkan endemic nephropathy and associated UTUC but also links it directly to UTUC in Taiwan. Because of the ubiquitous use of Aristolochia plants in these herbal remedies, a public health problem of considerable magnitude is anticipated in Asian countries. Gene expression signatures reveal some differential expression in bladder carcinoma, such as CLCA2 and GABRE. Few urinary markers have proven utility for the diagnosis and follow-up of UTUC, and no tissue or blood-based markers are currently undergoing clinical application. Novel endoscopic therapies provide some hope of improving tissue sampling, diagnosis, and kidney-sparing therapeutics, but the greatest potential lies in improving clinical (preoperative) risk stratification, which is critically limited in this disease. Biomarkers, currently untested, hold promise in identifying patients most likely to benefit from perioperative chemotherapy and at high risk from cisplatin-induced nephrotoxicity., Conclusions: Despite its rarity in the West, UTUC is reaching potentially epidemic proportions in the East because of exposure to carcinogenic herbal remedies. Critical trials are needed to improve our understanding and treatment of UTUC. Because of the broad range of comorbid conditions in patients suffering from this disease, it is the consensus of the participants that future clinical trials should be practical in design and applicable to a broad range of patients, diverging from the current dogma of narrow patient selection criteria in clinical trials. Practical designs would maximize accrual for a still uncommon disease, and their findings would be applicable to a larger proportion of patients than current narrowly selected designs., (© 2013 Elsevier Inc. All rights reserved.)
- Published
- 2014
- Full Text
- View/download PDF
20. Combination of a novel gene expression signature with a clinical nomogram improves the prediction of survival in high-risk bladder cancer.
- Author
-
Riester M, Taylor JM, Feifer A, Koppie T, Rosenberg JE, Downey RJ, Bochner BH, and Michor F
- Subjects
- Adult, Aged, Aged, 80 and over, Cohort Studies, Female, Gene Expression Regulation, Neoplastic, Humans, Male, Middle Aged, Prognosis, Recurrence, Reproducibility of Results, Survival Analysis, Urinary Bladder Neoplasms pathology, Gene Expression Profiling, Urinary Bladder Neoplasms genetics, Urinary Bladder Neoplasms mortality
- Abstract
Purpose: We aimed to validate and improve prognostic signatures for high-risk urothelial carcinoma of the bladder., Experimental Design: We evaluated microarray data from 93 patients with bladder cancer managed by radical cystectomy to determine gene expression patterns associated with clinical and prognostic variables. We compared our results with published bladder cancer microarray data sets comprising 578 additional patients and with 49 published gene signatures from multiple cancer types. Hierarchical clustering was utilized to identify subtypes associated with differences in survival. We then investigated whether the addition of survival-associated gene expression information to a validated postcystectomy nomogram utilizing clinical and pathologic variables improves prediction of recurrence., Results: Multiple markers for muscle invasive disease with highly significant expression differences in multiple data sets were identified, such as fibronectin 1 (FN1), NNMT, POSTN, and SMAD6. We identified signatures associated with pathologic stage and the likelihood of developing metastasis and death from bladder cancer, as well as with two distinct clustering subtypes of bladder cancer. Our novel signature correlated with overall survival in multiple independent data sets, significantly improving the prediction concordance of standard staging in all data sets [mean ΔC-statistic: 0.14; 95% confidence interval (CI), 0.01-0.27; P < 0.001]. Tested in our patient cohort, it significantly enhanced the performance of a postoperative survival nomogram (ΔC-statistic: 0.08, 95% CI, -0.04-0.20; P < 0.005)., Conclusions: Prognostic information obtained from gene expression data can aid in posttreatment prediction of bladder cancer recurrence. Our findings require further validation in external cohorts and prospectively in a clinical trial setting.
- Published
- 2012
- Full Text
- View/download PDF
21. Pretreatment imaging can be used to select imaging guidance, ultrasound alone versus CT plus ultrasound, for percutaneous renal radiofrequency ablation.
- Author
-
McGahan JP, Loh S, Fitzgerald E, Koppie T, Evans CP, Dall'Era M, and Li CS
- Subjects
- Adult, Aged, Aged, 80 and over, Contrast Media administration & dosage, Gadolinium DTPA administration & dosage, Humans, Iohexol administration & dosage, Kidney Neoplasms diagnostic imaging, Logistic Models, Middle Aged, Postoperative Complications, Retrospective Studies, Statistics, Nonparametric, Treatment Outcome, Catheter Ablation, Kidney Neoplasms surgery, Radiography, Interventional, Tomography, X-Ray Computed, Ultrasonography, Interventional
- Abstract
Objective: Although CT is most commonly used for guidance of radiofrequency ablation (RFA) of renal masses, other publications have shown that ultrasound alone may be used. Therefore, we compared the complications and technical effectiveness of renal RFA guided by ultrasound alone versus combined CT and ultrasound guidance., Materials and Methods: We retrospectively analyzed outcomes and complications of percutaneous renal RFA in two groups of patients for whom RFA was guided by either ultrasound alone (group 1) or combined CT and ultrasound (group 2). The sole factor in determining the method of guidance was preablation imaging. All other technical factors were consistent between the two groups., Results: There were 28 masses in 27 patients in group 1 and 32 masses in 29 patients in group 2. There was an overall major complication rate of 3.3% (2/60). Major complications occurred equally in group 2 (3.1% [1/32]) compared with group 1 (3.6% [1/28]). Overall ablative effectiveness was 93% (26/28) in group 1 and 84% (27/32) in group 2. There was no statistical difference between the two groups., Conclusion: In proper hands, sonography guidance alone is a safe and effective method for performance of renal RFA in preselected cases and can decrease CT utilization. The use of CT is reserved for situations in which pretreatment RFA imaging suggests difficulty in ultrasound mass visualization or when the mass is in close proximity to structures that may be injured by thermal ablation.
- Published
- 2011
- Full Text
- View/download PDF
22. Prognostic impact of the 2009 UICC/AJCC TNM staging system for renal cell carcinoma with venous extension.
- Author
-
Martínez-Salamanca JI, Huang WC, Millán I, Bertini R, Bianco FJ, Carballido JA, Ciancio G, Hernández C, Herranz F, Haferkamp A, Hohenfellner M, Hu B, Koppie T, Martínez-Ballesteros C, Montorsi F, Palou J, Pontes JE, Russo P, Terrone C, Villavicencio H, Volpe A, and Libertino JA
- Subjects
- Adult, Aged, Aged, 80 and over, Carcinoma, Renal Cell mortality, Carcinoma, Renal Cell surgery, Chi-Square Distribution, Europe, Female, Humans, Kaplan-Meier Estimate, Kidney Neoplasms mortality, Kidney Neoplasms surgery, Male, Middle Aged, Neoplasm Invasiveness, Nephrectomy, Predictive Value of Tests, Proportional Hazards Models, Renal Veins surgery, Retrospective Studies, Risk Assessment, Risk Factors, Societies, Medical, Survival Rate, Thrombectomy, Time Factors, Treatment Outcome, United States, Vena Cava, Inferior surgery, Venous Thrombosis mortality, Venous Thrombosis surgery, Carcinoma, Renal Cell pathology, Kidney Neoplasms pathology, Neoplasm Staging methods, Renal Veins pathology, Vena Cava, Inferior pathology, Venous Thrombosis pathology
- Abstract
Background: The prognostic significance of venous involvement and tumour thrombus level in renal cell carcinoma (RCC) remains highly controversial. In 2010, the American Joint Committee on Cancer (AJCC) and the Union International Centre le Cancer (UICC) revised the RCC staging system (7th edition) based on tumour thrombus level, differentiating the T stage of tumours limited to renal-vein-only involvement., Objective: We aimed to evaluate the impact of tumour thrombus extension in a multi-institutional cohort of patients., Design, Setting, and Participants: An international consortium of 11 institutions was established to retrospectively review a combined cohort of 1215 patients undergoing radical nephrectomy and tumour thrombectomy for RCC, including 585 patients with inferior vena cava (IVC) involvement or higher., Measurements: Predictive factors of survival, including histology, tumour thrombus level, nodal status, Fuhrman grade, and tumour size, were analysed., Results and Limitations: A total of 1122 patients with complete data were reviewed. The median follow-up for all patients was 24.7 mo, with a median survival of 33.8 mo. The 5-yr survival was 43.2% (renal vein involvement), 37% (IVC below the diaphragm), and 22% with caval involvement above the diaphragm. On multivariate analysis, tumour size (hazard ratio [HR]: 1.64 [range: 1.03-2.59]; p=0.036), Fuhrman grade (HR: 2.26 [range: 1.65-3.1]; p=0.000), nodal metastasis (HR: 1.32 [range: 1.09-1.67]; p=0.005), and tumour thrombus level (HR: 2.10 [range: 1.53-3.0]; p=0.00) correlated independently with survival., Conclusions: Based on analysis of the largest known cohort of patients with RCC along with IVC and atrial thrombus involvement, tumour thrombus level is an independent predictor of survival. Our findings support the changes to the latest AJCC/UICC staging system., (Copyright © 2010 European Association of Urology. Published by Elsevier B.V. All rights reserved.)
- Published
- 2011
- Full Text
- View/download PDF
23. NEDD4-1 is a proto-oncogenic ubiquitin ligase for PTEN.
- Author
-
Wang X, Trotman LC, Koppie T, Alimonti A, Chen Z, Gao Z, Wang J, Erdjument-Bromage H, Tempst P, Cordon-Cardo C, Pandolfi PP, and Jiang X
- Subjects
- Animals, Cell Transformation, Neoplastic, Endosomal Sorting Complexes Required for Transport, HeLa Cells, Humans, Mice, Nedd4 Ubiquitin Protein Ligases, Neoplasm Transplantation, Neoplasms pathology, Polyubiquitin metabolism, Protein Processing, Post-Translational, Protein Structure, Tertiary, Proto-Oncogene Mas, RNA Interference, Substrate Specificity, Ubiquitin-Protein Ligases chemistry, Ubiquitin-Protein Ligases deficiency, Ubiquitin-Protein Ligases isolation & purification, PTEN Phosphohydrolase metabolism, Proto-Oncogenes, Ubiquitin-Protein Ligases metabolism
- Abstract
The tumor suppressor PTEN, a critical regulator for multiple cellular processes, is mutated or deleted frequently in various human cancers. Subtle reductions in PTEN expression levels have profound impacts on carcinogenesis. Here we show that PTEN level is regulated by ubiquitin-mediated proteasomal degradation, and purified its ubiquitin ligase as HECT-domain protein NEDD4-1. In cells NEDD4-1 negatively regulates PTEN stability by catalyzing PTEN polyubiquitination. Consistent with the tumor-suppressive role of PTEN, overexpression of NEDD4-1 potentiated cellular transformation. Strikingly, in a mouse cancer model and multiple human cancer samples where the genetic background of PTEN was normal but its protein levels were low, NEDD4-1 was highly expressed, suggesting that aberrant upregulation of NEDD4-1 can posttranslationally suppress PTEN in cancers. Elimination of NEDD4-1 expression inhibited xenotransplanted tumor growth in a PTEN-dependent manner. Therefore, NEDD4-1 is a potential proto-oncogene that negatively regulates PTEN via ubiquitination, a paradigm analogous to that of Mdm2 and p53.
- Published
- 2007
- Full Text
- View/download PDF
24. Bladder cancer stage and outcome by array-based comparative genomic hybridization.
- Author
-
Blaveri E, Brewer JL, Roydasgupta R, Fridlyand J, DeVries S, Koppie T, Pejavar S, Mehta K, Carroll P, Simko JP, and Waldman FM
- Subjects
- Chromosome Mapping, Chromosomes, Artificial, Bacterial, Cluster Analysis, DNA chemistry, DNA metabolism, Disease Progression, Gene Deletion, Gene Expression Profiling, Genetic Linkage, Humans, Image Processing, Computer-Assisted, Multivariate Analysis, Oligonucleotide Array Sequence Analysis, Phenotype, Prognosis, Proportional Hazards Models, Time Factors, Treatment Outcome, Gene Expression Regulation, Neoplastic, Genome, Nucleic Acid Hybridization, Urinary Bladder Neoplasms diagnosis, Urinary Bladder Neoplasms genetics
- Abstract
Purpose: Bladder carcinogenesis is believed to follow alternative pathways of disease progression driven by an accumulation of genetic alterations. The purpose of this study was to evaluate associations between measures of genomic instability and bladder cancer clinical phenotype., Experimental Design: Genome-wide copy number profiles were obtained for 98 bladder tumors of diverse stages (29 pT(a), 14 pT1, 55 pT(2-4)) and grades (21 low-grade and 8 high-grade superficial tumors) by array-based comparative genomic hybridization (CGH). Each array contained 2,464 bacterial artificial chromosome and P1 clones, providing an average resolution of 1.5 Mb across the genome. A total of 54 muscle-invasive cases had follow-up information available. Overall outcome analysis was done for patients with muscle-invasive tumors having "good" (alive >2 years) versus "bad" (dead in <2 years) prognosis., Results: Array CGH analysis showed significant increases in copy number alterations and genomic instability with increasing stage and with outcome. The fraction of genome altered (FGA) was significantly different between tumors of different stages (pT(a) versus pT1, P = 0.0003; pT(a) versus pT(2-4), P = 0.02; and pT1 versus pT(2-4), P = 0.03). Individual clones that differed significantly between different tumor stages were identified after adjustment for multiple comparisons (false discovery rate < 0.05). For muscle-invasive tumors, the FGA was associated with patient outcome (bad versus good prognosis patients, P = 0.002) and was identified as the only independent predictor of overall outcome based on a multivariate Cox proportional hazards method. Unsupervised hierarchical clustering separated "good" and "bad" prognosis muscle-invasive tumors into clusters that showed significant association with FGA and survival (Kaplan-Meier, P = 0.019). Supervised tumor classification (prediction analysis for microarrays) had a 71% classification success rate based on 102 unique clones., Conclusions: Array-based CGH identified quantitative and qualitative differences in DNA copy number alterations at high resolution according to tumor stage and grade. Fraction genome altered was associated with worse outcome in muscle-invasive tumors, independent of other clinicopathologic parameters. Measures of genomic instability add independent power to outcome prediction of bladder tumors.
- Published
- 2005
- Full Text
- View/download PDF
25. Bladder cancer outcome and subtype classification by gene expression.
- Author
-
Blaveri E, Simko JP, Korkola JE, Brewer JL, Baehner F, Mehta K, Devries S, Koppie T, Pejavar S, Carroll P, and Waldman FM
- Subjects
- Aged, Carcinoma, Squamous Cell genetics, Carcinoma, Squamous Cell metabolism, Carcinoma, Squamous Cell pathology, Carcinoma, Transitional Cell genetics, Carcinoma, Transitional Cell metabolism, Carcinoma, Transitional Cell pathology, Cell Line, Tumor, Cluster Analysis, Cyclin A analysis, Cyclin A2, Female, Gene Expression Regulation, Neoplastic genetics, HL-60 Cells, Humans, Immunohistochemistry, Male, Neoplasm Staging, Oligonucleotide Array Sequence Analysis methods, Parathyroid Hormone-Related Protein analysis, Prognosis, Urinary Bladder Neoplasms classification, Urinary Bladder Neoplasms metabolism, Gene Expression Profiling, Urinary Bladder Neoplasms genetics
- Abstract
Models of bladder tumor progression have suggested that genetic alterations may determine both phenotype and clinical course. We have applied expression microarray analysis to a divergent set of bladder tumors to further elucidate the course of disease progression and to classify tumors into more homogeneous and clinically relevant subgroups. cDNA microarrays containing 10,368 human gene elements were used to characterize the global gene expression patterns in 80 bladder tumors, 9 bladder cancer cell lines, and 3 normal bladder samples. Robust statistical approaches accounting for the multiple testing problem were used to identify differentially expressed genes. Unsupervised hierarchical clustering successfully separated the samples into two subgroups containing superficial (pT(a) and pT(1)) versus muscle-invasive (pT(2)-pT(4)) tumors. Supervised classification had a 90.5% success rate separating superficial from muscle-invasive tumors based on a limited subset of genes. Tumors could also be classified into transitional versus squamous subtypes (89% success rate) and good versus bad prognosis (78% success rate). The performance of our stage classifiers was confirmed in silico using data from an independent tumor set. Validation of differential expression was done using immunohistochemistry on tissue microarrays for cathepsin E, cyclin A2, and parathyroid hormone-related protein. Genes driving the separation between tumor subsets may prove to be important biomarkers for bladder cancer development and progression and eventually candidates for therapeutic targeting.
- Published
- 2005
- Full Text
- View/download PDF
26. Transperineal prostate biopsy after abdominoperineal resection.
- Author
-
Shinohara K, Gulati M, Koppie T, and Terris MK
- Subjects
- Aged, Colitis, Ulcerative surgery, Colonic Neoplasms surgery, Humans, Male, Middle Aged, Prostate-Specific Antigen blood, Abdominal Wall surgery, Biopsy, Needle methods, Perineum surgery, Prostate pathology, Prostatic Neoplasms diagnosis, Ultrasonography, Interventional
- Abstract
Purpose: Prostate cancer evaluation in men who have undergone abdominoperineal resection poses a challenge for urologists. Diagnosis and staging methods are limited because as access to the prostate via digital rectal examination is not possible. Prostate specific antigen (PSA) has been used to screen for malignancy in this population. However, the conventional diagnostic technique with transrectal ultrasound guided biopsies cannot be used. Transperineal ultrasound and biopsy have been described to evaluate the prostate in this setting. We report our experience with transperineal ultrasound biopsy for evaluating the prostate in patients with elevated PSA who have previously undergone abdominoperineal resection., Materials and Methods: We reviewed the records of 28 patients treated at 2 institutions. All patients had a history of abdominoperineal resection and subsequent transperineal ultrasound guided prostate biopsy for evaluating elevated PSA. Mean serum PSA in this population was 22 ng./ml. (median 9.5, range 4.1 to 237). Abdominoperineal resection was done in 16 patients (57%) for colorectal cancer, in 11 (39%) for ulcerative colitis and in 1 (4%) for familial polyposis coli. Average time since resection was 14 years (range 1 to 33). Five patients had previously undergone radiation therapy as part of treatment for colorectal cancer before transperineal ultrasound biopsy., Results: Of the 28 biopsies performed 23 revealed prostate cancer, 2 revealed prostatitis and 3 were benign. Average Gleason grade was 6.6 (range 3 to 9). Of the 23 patients with prostate cancer 22 were treated with androgen deprivation therapy (7), prostatectomy (8), external beam (6) and high dose (1) radiation therapy. Of the 8 patients who underwent prostatectomy pathological stage was T2 in 3 and T3 in 4, while pathological findings were not determined in 1 patient in whom the prostate was removed in pieces., Conclusions: In patients with a history of abdominoperineal resection and elevated PSA transperineal ultrasound guided biopsy of the prostate can provide an accurate tissue diagnosis.
- Published
- 2003
- Full Text
- View/download PDF
27. Kidney morcellation in laparoscopic nephrectomy for tumor: recommendations for specimen sampling and pathologic tumor staging.
- Author
-
Rabban JT, Meng MV, Yeh B, Koppie T, Ferrell L, and Stoller ML
- Subjects
- Algorithms, Carcinoma, Renal Cell diagnostic imaging, Carcinoma, Renal Cell pathology, Decision Support Techniques, Humans, Kidney Neoplasms diagnostic imaging, Kidney Neoplasms pathology, Kidney Pelvis diagnostic imaging, Kidney Pelvis pathology, Laparoscopy, Radiography, Urothelium pathology, Carcinoma, Renal Cell surgery, Kidney Neoplasms surgery, Neoplasm Staging methods, Nephrectomy methods, Specimen Handling methods
- Abstract
Laparoscopic nephrectomy is a novel approach for small renal tumors in selected patients; however, removal of the kidney through the small laparoscopic abdominal wall incision site requires the kidney to be morcellated into small fragments while still in situ. Morcellation presents two problems for the pathologist. First, guidelines for optimal sampling of morcellated fragments have not been described. Second, morcellation precludes complete pTNM tumor staging, in particular, tumor size, margins, and renal vein involvement. Based on our initial experience with 23 laparoscopic nephrectomies/nephroureterectomies (13 clinically suspected neoplasms, confirmed pathologically as renal cell carcinoma [RCC, n = 7], urothelial carcinoma of the renal pelvis [n = 3], angiomyolipoma [n = 1], and cystic nephroma [n = 1], and 10 clinically benign entities) and a conservative statistical model, we present a decision analysis model of various specimen sampling protocols that optimize cost, labor, or time to diagnosis (single vs sequential sampling). Using the tumor-to-kidney volume ratio (TKR), calculated from preoperative radiologic imaging and specimen gross weight, several specimen sampling algorithms were compared. For the average situation in which TKR is > or =0.15, the algorithm that most significantly optimizes cost and labor is one that initially samples 5% of the morcellated specimen. However, additional sampling may be required in one fourth of the cases. The optimal amount of sampled tissue may indeed be less than 5% because this assumes no suspicious tissue is grossly visible and in all our cases of RCC grossly visible tumor was identified. Additional nomograms for a spectrum of TKR, sampling success, and cost are presented to allow pathologists their own discretion in determining optimal sampling of the morcellated kidney. Tumor staging is severely limited by morcellation. Tumor size, renal capsule involvement, and renal vein involvement cannot be fully pathologically evaluated for RCC, whereas invasion cannot be definitively assessed for urothelial carcinoma of the renal pelvis. Knowledge of the radiologic features (lesion size, capsule, and vein involvement) is important in sampling and staging morcellated kidneys removed laparoscopically.
- Published
- 2001
- Full Text
- View/download PDF
28. Is anastomotic biopsy necessary before radiotherapy after radical prostatectomy?
- Author
-
Koppie TM, Grossfeld GD, Nudell DM, Weinberg VK, and Carroll PR
- Subjects
- Aged, Follow-Up Studies, Humans, Male, Middle Aged, Multivariate Analysis, Neoplasm Recurrence, Local mortality, Probability, Proportional Hazards Models, Prostatectomy methods, Prostatic Neoplasms mortality, Radiotherapy, Adjuvant, Sensitivity and Specificity, Survival Rate, Time Factors, Treatment Outcome, Biopsy, Needle methods, Neoplasm Recurrence, Local pathology, Neoplasm Recurrence, Local radiotherapy, Prostate-Specific Antigen blood, Prostatic Neoplasms pathology, Prostatic Neoplasms surgery
- Abstract
Purpose: External beam radiotherapy may be given after radical prostatectomy as adjuvant (immediate) or therapeutic (delayed) treatment, the latter in response to evidence of disease recurrence. In patients receiving delayed radiotherapy the necessity of a positive anastomotic biopsy before treatment remains unclear. We determined whether a positive anastomotic biopsy predicted the response to radiation in this setting., Materials and Methods: We reviewed the records of 67 patients who received radiotherapy for biochemical or biopsy proved recurrent prostate cancer after radical prostatectomy. Patients underwent surgery at our institution or its affiliated hospitals, or were referred to our institution for radiotherapy. All patients had a negative metastatic evaluation before receiving radiotherapy. Biochemical failure after radiotherapy was defined as serum prostate specific antigen (PSA) 0.2 ng./dl. or greater on 2 or more consecutive occasions. Biochemical recurrence-free survival was calculated using the Kaplan-Meier method. Independent predictors of PSA failure after radiotherapy were identified using the multivariate Cox proportional hazards model., Results: Of the 67 patients evaluated 33 and 34 received radiotherapy for biochemical failure and biopsy proved local recurrence, respectively. The 3-year recurrence-free survival rate was 49% in patients treated for biochemical failure and 39% in those with biopsy proved local recurrence. There was no significant difference in PSA-free survival in these 2 groups. Only pre-radiotherapy PSA 1 ng./dl. or greater (p = 0.02) and seminal vesicle invasion (p = 0.02) were significant independent predictors of biochemical failure., Conclusions: A positive anastomotic biopsy did not predict an improved outcome after radiotherapy following radical prostatectomy. Anastomotic biopsy was associated with a longer time to salvage radiotherapy. However, this delay did not translate into worse disease-free outcomes in patients who underwent anastomotic biopsy. High pre-radiotherapy PSA greater than 1 ng./ml. was the most significant predictor of biochemical failure after therapeutic radiotherapy. Decisions regarding local radiation therapy after radical prostatectomy may be made without documenting recurrent local disease.
- Published
- 2001
29. Patterns of treatment of patients with prostate cancer initially managed with surveillance: results from The CaPSURE database. Cancer of the Prostate Strategic Urological Research Endeavor.
- Author
-
Koppie TM, Grossfeld GD, Miller D, Yu J, Stier D, Broering JM, Lubeck D, Henning JM, Flanders SC, and Carroll PR
- Subjects
- Aged, Databases, Factual, Humans, Male, Middle Aged, Population Surveillance, Practice Patterns, Physicians', Prostate-Specific Antigen blood, Prostatic Neoplasms blood, Prostatic Neoplasms mortality, Registries, Survival Rate, Prostatic Neoplasms therapy
- Abstract
Purpose: We determined the demographic and clinical profile of men who elect surveillance as the initial management of prostate cancer as well as the incidence and predictors of secondary treatment of these patients., Materials and Methods: The Cancer of the Prostate Strategic Urological Research Endeavor (CaPSURE) is a national disease registry of patients with various stages and treatments of prostate cancer. Using this database of 4,458 men we identified 329 (8.2%) who elected surveillance as the initial management of prostate cancer. Patients choosing watchful waiting were compared to other CaPSURE participants using the chi-square test. The likelihood of treatment initiation in the watchful waiting group was calculated using the Kaplan-Meier method. After adjusting for patient age, race, prostate specific antigen (PSA) at diagnosis, clinical T stage and total Gleason score the Cox proportional hazards regression model was used to determine significant predictors of treatment initiation., Results: Compared with others in the database, patients on watchful waiting were more likely to be 75 years old or older (51% versus 16%, p <0.001), white (93% versus 85%, p <0.001), and have lower serum PSA (p <0.001), organ confined disease (97% versus 88%, p <0.001) and a total Gleason score of 7 or less (97% versus 88%, p <0.001). In the watchful waiting group there was a 52% likelihood of treatment initiation within 5 years of the diagnosis. Significant predictors of secondary treatment were age younger than 65 years and elevated serum PSA at diagnosis. Neither race, extraprostatic stage cT3 disease nor higher total Gleason score was a significant predictor of treatment., Conclusions: Men who elect initial watchful waiting for prostate cancer tend to be older, have lower serum PSA and more favorable disease characteristics than those who seek treatment. PSA at diagnosis is the dominant factor for predicting secondary treatment.
- Published
- 2000
30. The efficacy of cryosurgical ablation of prostate cancer: the University of California, San Francisco experience.
- Author
-
Koppie TM, Shinohara K, Grossfeld GD, Presti JC Jr, and Carroll PR
- Subjects
- Actuarial Analysis, Aged, Aged, 80 and over, Biopsy, Hospitals, University, Humans, Male, Middle Aged, Neoplasm Staging, Prostate-Specific Antigen blood, Prostatic Neoplasms blood, Prostatic Neoplasms mortality, Prostatic Neoplasms pathology, San Francisco, Survival Rate, Cryosurgery, Prostatic Neoplasms surgery
- Abstract
Purpose: We analyze biopsy and prostate specific antigen (PSA) results following cryosurgery for patients with clinically localized prostate cancer., Materials and Methods: A total of 176 patients underwent 207 cryosurgical procedures for clinically localized (stages T1 to T4) prostate cancer using a multiprobe cryosurgical device. Cancer stage was T1 in 8.7%, T2 in 30%, T3 in 59% and T4 in 2.3% of the 176 patients. Neoadjuvant androgen deprivation was delivered to 101 patients (57%). End points used to determine efficacy of the procedure included analysis of posttreatment serum PSA characteristics (nadir and nonrising status) and biopsy results (absence of cancer). Cryosurgery was considered successful if PSA reached a nadir of less than 0.5 ng./ml. and did not increase by more than 0.2 ng./ml. on 2 consecutive occasions. Mean followup for the entire group was 30.8 months, with 122 patients (60%) followed for 24 or more months and 75 (36%) followed for 36 or more months., Results: Serial PSA data was available after 181 initial and repeat procedures. Nadir PSA was undetectable in 88 patients (49%), between 0.1 and 0.4 ng./ml. in 39 (21%) and 0.5 ng./ml. or greater in 54 (30%) following cryosurgery. After 78 of these procedures (43%) serum PSA reached a nadir of less than 0.5 ng./ml. and failed to increase greater than 0.2 ng./ml. on at least 2 occasions. Prostate biopsy was performed following 167 procedures and was positive after 64 (38%)., Conclusions: Cryosurgery was associated with favorable serum PSA characteristics in 49% of patients 3 years after treatment. Undetectable PSA nadir and pretreatment PSA 10 ng./ml. or less were associated with a favorable outcome, with a biochemical disease-free survival of 77% and 61% 3 years after treatment, respectively.
- Published
- 1999
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.